Roche’s Ventana MMR RxDx Panel Test Receives the US FDA’s Approval as First CDx to Detect dMMR Solid Tumor

August 20, 2021 Auto Bot approval, FDA, MedTech, regulatory, Roche 0

Shots:

  • The FDA has approved the Ventana MMR RxDx Panel test as a CDx to identify patients with dMMR advanced solid tumors, who may be eligible for Jemperli monothx., based on the results of the MMR biomarker test
  • Ventana MMR RxDx Panel provides access to clinicians with fully automated panel of MMR biomarkers tested by IHC
  • The test assesses the expression of MMR proteins in FFPE tumor tissues. The test and Jemperli were earlier received approval for use in endometrial cancer in Apr’2021

Click here to­ read full press release/ article | Ref: Roche | Image: Switzerland Global Enterprise

The post Roche’s Ventana MMR RxDx Panel Test Receives the US FDA’s Approval as First CDx to Detect dMMR Solid Tumor first appeared on PharmaShots.